Skip to content

New form of brain stimulation targeting dorsomedial prefrontal cortex in treating refractory depression and the predictive biomarkers of antidepressant efficacy

New form of brain stimulation targeting dorsomedial prefrontal cortex in treating refractory depression and the predictive biomarkers of antidepressant efficacy - Direct comparisons of antidepressant and anti-anxiosomatic effects between 20Hz rTMS, piTBS and sham intervention

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000047897
Enrollment
75
Registered
2022-05-31
Start date
2022-05-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A treatment option for Medication-resistant depression

Interventions

Bilateral DMPFC prolonged intermittent theta-burst stimulation (piTBS) group (2 sessions/hemisphere/day, 5 days/week,total 2 weeks)
80% active motor threshold, 1800 pulses/session Bilateral DMPFC 20Hz-rTMS group (2 sessions/hemisphere/day, 5 days/week,total 2 weeks)
100% resting motor threshold, 2000 pulses/session Sham group (2 sessions/hemisphere/day, 5 days/week, total 2 weeks)
randomly divided to half with piTBS and half with rTMS parameters using a sham coil.

Sponsors

Taipei Veterans General Hospital, Taipei, Taiwan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) adult patients with the relapse of major depressive episode (2) Severity: 17 items HDRS >=18; CGI>=4 (3) Poor response to at least one antidepressant (4) keep the antidepressant and its dosage at least 4 weeks before entering the trial; no adjustment of antidepressant during the trial.

Exclusion criteria

Exclusion criteria: Patients with schizophrenia, bipolar I&II disorder, organic mental disorder and major physical illness; with brain implants or cardiac pacemakers; pregnancy; or who having strong suicidal risk; poor response to previous ECT or 10Hz left DLPFC rTMS/piTBS; claustrophobia for MRI screening; patients who cannot cooperate the trial protocol

Design outcomes

Primary

MeasureTime frame
the changing of17-items Hamilton Depression Rating Scale (HDRS-17,week-2 vs. baseline) in response to the 2-week DMPFC brain stimulation.

Secondary

MeasureTime frame
baseline and the changing of resting state functional and structural connectivity, EEG, paired-pulse TMS-EEG; Cognitive function; Response rate and remission rate, evaluated by HDRS-17; the changing of anxiosomatic cluster symptoms derived from HDRS-17, dysphoric cluster symptoms derived from HDRS-17, Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale(HAM-A), depression subscale and somatic subscale of Depression and Somatic Symptoms Scale (DSSS), Clinical Global Index (CGI),Young Mania Rating Scale (YMRS),Rumination response scale (RRS), Snaith-Hamilton Pleasure Scale (SHAPS), UCLA loneliness scale, Difficulties in Emotion Regulation Scale (DERS), Taiwan Cognition. Questionnaire (TCQ); the predictive values of Maudsley Staging method for refractoriness and TRD severity scale (TRDSS).

Countries

Asia(except Japan)

Contacts

Public ContactChih-Ming Cheng

Taipei Veterans General Hospital, Taipei, Taiwan Department of Psychiatry

vdodaco@gmail.com88628757027

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026